More CREDENCE for SGLT2 Inhibition

被引：14
作者：
Verma, Subodh [1 ]
Bhatt, Deepak L. [2 ]
机构：
[1] Univ Toronto, St Michaels Hosp, Div Cardiac Surg, 8th Floor,Bond Wing,30 Bond St, Toronto, ON M5B 1W8, Canada
[2] Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA
来源：
CIRCULATION | 2019年 / 140卷 / 18期
关键词：
cardiovascular diseases; diabetes mellitus; diabetic nephropathies; kidney failure; chronic;
D O I：
10.1161/CIRCULATIONAHA.119.041181
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1448 / 1450
页数：3
相关论文
共 50 条
[41]   Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study [J].
Jeong, Su Jin ;
Lee, Seung Eun ;
Shin, Dong Hyun ;
Park, Ie Byung ;
Lee, Hui Seung ;
Kim, Kyoung-Ah .
BMC NEPHROLOGY, 2021, 22 (01)
[42]   SGLT2 inhibitors: Beyond glycemic control [J].
Hasan, Irtiza ;
Rashid, Tasnuva ;
Jaikaransingh, Vishal ;
Heilig, Charles ;
Abdel-Rahman, Emaad M. ;
Awad, Alaa S. .
JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2024, 35
[43]   SGLT2 Inhibitors: The Sweet Success for Kidneys [J].
Dharia, Atit ;
Khan, Abid ;
Sridhar, Vikas S. ;
Cherney, David Z., I .
ANNUAL REVIEW OF MEDICINE, 2023, 74 :369-384
[44]   Roles for SGLT2 Inhibitors in Cardiorenal Disease [J].
Green, Jennifer B. ;
McCullough, Peter A. .
CARDIORENAL MEDICINE, 2022, 12 (03) :81-93
[45]   Efficacy and cardiovascular safety of SGLT2 Inhibitors [J].
Fernandez, Cornelius James ;
Nevins, Abisha Graciano ;
Nawaz, Shasta ;
Nazir, Tahir ;
Hanna, Fahmy W. F. .
CURRENT DRUG SAFETY, 2021, 16 (02) :178-196
[46]   Synthetic Strategies toward SGLT2 Inhibitors [J].
Aguillon, Anderson R. ;
Mascarello, Alessandra ;
Segretti, Natanael D. ;
de Azevedo, Hatylas F. Z. ;
Guimaraes, Cristiano R. W. ;
Miranda, Leandro S. M. ;
de Souza, Rodrigo O. M. A. .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2018, 22 (04) :467-488
[47]   SGLT2 Inhibitors: Benefit/Risk Balance [J].
Scheen, Andre J. .
CURRENT DIABETES REPORTS, 2016, 16 (10)
[48]   Renal and cardiac effects of SGLT2 inhibitors [J].
Menne J. .
Der Nephrologe, 2017, 12 (2) :90-96
[49]   SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes [J].
Chen, Huan ;
Birnbaum, Yochai ;
Ye, Regina ;
Yang, Hsiu-Chiung ;
Bajaj, Mandeep ;
Ye, Yumei .
CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (06) :1091-1108
[50]   SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes [J].
Huan Chen ;
Yochai Birnbaum ;
Regina Ye ;
Hsiu-Chiung Yang ;
Mandeep Bajaj ;
Yumei Ye .
Cardiovascular Drugs and Therapy, 2022, 36 :1091-1108
12345